Ilko Menkov Portfolio
Invests via Vestal Point Capita LLP | Managed by Ryan Wilder
Invests via Vestal Point Capita LLP
Managed by Ryan Wilder
Automatically Tracked
Ilko Menkov Profile
With a robust background in strategic investments and financial management, Ilko Menkov is an influential figure within the European private equity landscape. His expertise encompasses extensive operational leadership, particularly in technology and innovation sectors, where he has played a pivotal role in scaling startups and driving sustainable growth. Leveraging deep market insights, he collaborates closely with entrepreneurs to enhance business models that foster resilience and expansion. This focus on value creation has established him as a respected investor-operator who continuously seeks transformative opportunities across various markets.
With a robust background in strategic investments and financial management, Ilko Menkov is an influential figure within the European private equity landscape. His expertise encompasses extensive operational leadership, particularly in technology and innovation sectors, where he has played a pivotal role in scaling startups and driving sustainable growth. Leveraging deep market insights, he collaborates closely with entrepreneurs to enhance business models that foster resilience and expansion. This focus on value creation has established him as a respected investor-operator who continuously seeks transformative opportunities across various markets.
Investment Philosophy & Strategy
Grounded in an extensive history of entrepreneurial ventures, Ilko Menkov applies a unique blend of operational insights and strategic foresight to his investment endeavors. His approach is primarily driven by identifying disruptive trends within technology sectors, enabling him to cultivate promising startups poised for exponential growth. By prioritizing partnerships with visionary founders, he aligns resources and expertise to optimize scalability and impact. This emphasis on transformative potential allows him to capitalize on market dynamics while fostering innovation that drives competitive advantage.
Grounded in an extensive history of entrepreneurial ventures, Ilko Menkov applies a unique blend of operational insights and strategic foresight to his investment endeavors. His approach is primarily driven by identifying disruptive trends within technology sectors, enabling him to cultivate promising startups poised for exponential growth. By prioritizing partnerships with visionary founders, he aligns resources and expertise to optimize scalability and impact. This emphasis on transformative potential allows him to capitalize on market dynamics while fostering innovation that drives competitive advantage.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
105.03%
Gain -1.14%
Monthly
2.23%
Yearly
30.27%
Drawdown
33.02%
$4.02B
Equity
Holdings
$4.02B
Investment
$3.69B
$1.42B
Profit -$34.05M
Realized
$1.09B
Unrealized
$329.91M
Dividends
$11.18M
Goals
Avg. 36% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-1.14%
Profit
-$34.05M
Win %
51%
This Week
Compared To Last Week
Gain
-2.82%
Profit
-$116.48M
Win %
51%
This Month
Compared to last month
Gain
-8.24%
Profit
-$361.19M
Win %
51%
This Year
Compared to last year
Gain
-5.53%
Profit
-$235.3M
Win %
60%
CBIO Crescent Biopharma, Inc.
+4.88%
+$1.33M 
TENX Tenax Therapeutics Inc.
+2.96%
+$2,939.14 
EVMN Evommune, Inc.
+2.46%
+$230,100 
TRAX First Tracks Biotherapeutics, Inc.
+2.16%
+$856,592.8 
IBIO iBio, Inc.
+2%
+$65,000 
DMRA Damora Therapeutics, Inc.
+1.98%
+$258,750 
OKUR OnKure Therapeutics Inc.
+1.35%
+$73,027.96 
ASND Ascendis Pharma A/S
+1.26%
+$1.13M 
BCRX BioCryst Pharmaceuticals Inc.
+1.21%
+$871,500 
SRZN Surrozen, Inc.
+1.16%
+$60,050.26 
ZBH Zimmer Biomet Holdings, Inc.
+0.73%
+$966,000 
APRE Clear Creek Independent School District
+0.72%
+$1,890 
LXEO Lexeo Therapeutics Inc.
+0.72%
+$129,600 
BCAX Bicara Therapeutics Inc.
+0.71%
+$840,000 
BBNX Beta Bionics Inc.
+0.65%
+$224,000 
VYGR Voyager Therapeutics Inc.
+0.64%
+$51,187.5 
GMED Globus Medical Inc.
+0.59%
+$374,000 
ELVN Enliven Therapeutics, Inc.
+0.56%
+$1.12M 
QURE uniQure N.V.
+0.52%
+$215,050 
ABT Abbott Laboratories
+0.44%
+$630,000 
AZN AstraZeneca PLC American Depositary Shares
+0.07%
+$49,500 
XENE Xenon Pharmaceuticals Inc.
-30.23%
-$12.14M 
SGP SpyGlass Pharma, Inc.
-6.21%
-$1.22M 
MYGN Myriad Genetics Inc.
-3.87%
-$918,747 
KLRA Kailera Therapeutics, Inc.
-3.41%
-$253,000 
DYN Dyne Therapeutics Inc.
-3.04%
-$1.86M 
RAPP Rapport Therapeutics Inc.
-2.57%
-$788,400 
TSHA Taysha Gene Therapies Inc.
-2.33%
-$2.33M 
RVMD Revolution Medicines Inc.
-2.31%
-$2.04M 
ZURA Zura Bio Ltd.
-2.08%
-$111,525.82 
PALI Palisade Bio Inc.
-2.06%
-$87,500 
ABVX Abivax SA ADR
-1.98%
-$4.98M 
RZLT Rezolute, Inc.
-1.73%
-$26,158.83 
AVR Anteris Technologies Ltd.
-1.7%
-$144,127 
MNPR Monopar Therapeutics Inc.
-1.6%
-$124,192.28 
SNY Sanofi American Depositary Receipt
-1.54%
-$1.33M 
IMTX Immatics N.V.
-1.53%
-$833,625 
NBIX Neurocrine Biosciences Inc.
-1.51%
-$4.31M 
ANRO Alto Neuroscience Inc.
-1.5%
-$365,025 
TRVI Trevi Therapeutics Inc.
-1.45%
-$682,000 
SGMT Sagimet Biosciences Inc.
-1.43%
-$85,672.32 
IMCR Immunocore Holdings plc American Depositary Receipt
-1.3%
-$756,000 
ZBIO Zenas BioPharma, Inc.
-1.25%
-$146,000 
NKTR Nektar Therapeutics Inc.
-1.17%
-$800,000 
NYXH Nyxoah SA
-1.01%
-$12,651.92 
PODD Insulet Corporation
-0.97%
-$924,600 
VKTX Viking Therapeutics Inc.
-0.89%
-$176,800 
SVRA Savara Inc.
-0.83%
-$122,400 
IRON Disc Medicine Inc.
-0.75%
-$806,000 
TECX Tectonic Therapeutic Inc.
-0.73%
-$85,000 
ARWR Arrowhead Pharmaceuticals Inc.
-0.72%
-$771,750 
SLDB Solid Biosciences Inc.
-0.56%
-$108,000 
ENGN enGene Therapeutics Inc.
-0.52%
-$16,674.3 
INSM Insmed Inc.
-0.48%
-$147,500 
NRIX Nurix Therapeutics Inc.
-0.47%
-$966,000 
OLMA Olema Pharmaceuticals Inc.
-0.4%
-$16,742.04 
RGEN Repligen Corporation
-0.38%
-$272,000 
GEHC GE HealthCare Technologies Inc.
-0.38%
-$110,250 
TARS Tarsus Pharmaceuticals Inc.
-0.34%
-$283,500 
BMRN Biomarin Pharmaceutical Inc.
-0.33%
-$1.3M 
REGN Regeneron Pharmaceuticals, Inc.
-0.31%
-$97,600.4 
UTHR United Therapeutics Corporation
-0.29%
-$632,920.65 
GLUE Monte Rosa Therapeutics, Inc.
-0.24%
-$138,000 
BMY Bristol-Myers Squibb Company
-0.2%
-$100,000 
MDGL Madrigal Pharmaceuticals, Inc.
-0.17%
-$58,176.3 
AVTX Avalo Therapeutics Inc.
-0.15%
-$19,375 
DRUG Bright Minds Biosciences Inc.
-0.11%
-$35,425 
ALC Alcon Inc.
-0.05%
-$15,000 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 688 | Longs Won 352/688 51% | Profit Factor 2.96 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $10.17M |
| Average Win $6.07M | Best Trade (Jun 30) $146.75M | Sharpe Ratio -22.1 |
| Average Loss -$2.15M | Worst Trade (Sep 18) -$26.99M | Z-Score -3.69 (100%) |
| Commissions $0 | Avg. Trade Length 7m 3w 4d | Expectancy $2.06M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,873 | 1,685 | 1,498 | 1,311 | 1,124 | 936 | 749 | 562 | 375 | 187 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | 1.4M | $127.04M | $143.75M | - | $16.72M | 13.16% | +0.44% |
| ABVX Abivax SA ADR | 2.35M | $285.51M | $246.39M | - | -$39.12M | -13.7% | -1.981% |
| ALC Alcon Inc. | 500,000 | $37.28M | $32.58M | - | -$4.7M | -12.61% | -0.046% |
| ANRO Alto Neuroscience Inc. | 785,000 | $13.97M | $23.95M | - | $9.98M | 71.43% | -1.501% |
| APRE Clear Creek Independent School District | 350,000 | $267,015 | $264,390 | - | -$2,625 | -0.98% | +0.72% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.57M | $99.49M | $105.92M | - | $6.43M | 6.46% | -0.723% |
| ASND Ascendis Pharma A/S | 375,000 | $100.02M | $90.77M | - | -$9.25M | -9.25% | +1.259% |
| AVR Anteris Technologies Ltd. | 1.01M | $5.61M | $8.36M | - | $2.75M | 49.14% | -1.695% |
| AVTX Avalo Therapeutics Inc. | 775,000 | $14.32M | $12.92M | - | -$1.41M | -9.82% | -0.15% |
| AZN AstraZeneca PLC American Depositary Shares | 450,000 | $86.09M | $74.81M | - | -$11.28M | -13.1% | +0.066% |
| BBNX Beta Bionics Inc. | 1.6M | $16.03M | $34.51M | - | $18.48M | 115.27% | +0.653% |
| BCAX Bicara Therapeutics Inc. | 5.25M | $73.03M | $119.44M | - | $46.41M | 63.54% | +0.708% |
| BCRX BioCryst Pharmaceuticals Inc. | 8.3M | $75.76M | $73.08M | - | -$2.68M | -3.53% | +1.207% |
| BMRN Biomarin Pharmaceutical Inc. | 6.03M | $346.99M | $390.81M | - | $43.82M | 12.63% | -0.33% |
| BMY Bristol-Myers Squibb Company | 800,000 | $48.18M | $50.17M | - | $1.99M | 4.12% | -0.199% |
| CBIO Crescent Biopharma, Inc. | 1.63M | $20.13M | $28.67M | - | $8.54M | 42.42% | +4.883% |
| DMRA Damora Therapeutics, Inc. | 575,000 | $14.89M | $13.36M | - | -$1.54M | -10.31% | +1.975% |
| DRUG Bright Minds Biosciences Inc. | 545,000 | $39.62M | $33.51M | - | -$6.11M | -15.43% | -0.106% |
| DYN Dyne Therapeutics Inc. | 3.38M | $61.19M | $59.1M | - | -$2.09M | -3.42% | -3.045% |
| ELVN Enliven Therapeutics, Inc. | 4M | $91.05M | $202.08M | - | $111.03M | 121.94% | +0.557% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Ilko Menkov?
The largest contributions to the portfolio's profits come from the following stocks: Revolution Medicines Inc - $213.72M, uniQure N.V - $212.08M, Tyra Biosciences, Inc - $66.91M, Dianthus Therapeutics Inc - $62.67M, and Terns Pharmaceuticals, Inc - $55.44M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Structure Therapeutics Inc - $28.23M, Geron Corporation - $24.28M, Alx Oncology Holdings Inc - $19.55M, Boston Scientific Corporation - $16.06M, and Astria Therapeutics Inc - $13.83M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Ilko Menkov's portfolio generate?
The portfolio generates substantial dividend income, with a total of $11.18M earned over time. The largest contributors to dividend income include Sanofi American Depositary Receipt - $3.39M, Bristol-Myers Squibb Company - $1.74M, Merck & Co., Inc - $1.61M, Abbott Laboratories - $1.51M, and GSK plc Sponsored ADR - $568,898.75. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Ilko Menkov's monthly returns?
Ilko Menkov's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Ilko Menkov's strategy be considered aggressive or moderate?
Ilko Menkov's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Ilko Menkov's strategy?
Ilko Menkov's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
